Long-acting Versus Standard Non-ergot Dopamine Agonists in Parkinson's Disease: a Meta-analysis of Randomized Controlled Trials

Overview

Journal CNS Neurosci Ther

Specialties Neurology
Pharmacology

Date 2014 Mar 5

PMID 24588909

Citations 5

Authors

Chang-Qing Zhou

Jing-He Lou

Yu-Ping Zhang

Ling Zhong

Ya-Lan Chen

Feng-Jiao Lu

Guo-Guang Peng

Affiliations

Soon will be listed here.

Abstract

Aims: To evaluate the efficacy, tolerability, and safety of long-acting versus standard non-ergot dopamine agonists (NEDAs) in Parkinson's disease (PD), we performed a meta-analysis of randomized controlled trials (RCTs).

Materials And Methods: The PubMed, EMBASE, Cochrane Library databases, and Web of Knowledge were searched up to November 20th 2013. The pooled weighted mean differences (WMDs) and relative risks (RRs) with 95% confidence intervals (CIs) were calculated.

Results: Eight large-scale RCTs, involving 2402 patients, were included in this meta-analysis. Compared with the standard NEDAs, long-acting NEDAs exhibited similar improvements in Unified Parkinson's Disease Rating Scale activities of daily living (ADL) score (WMD 0.09, 95% CI -0.33 to 0.50), motor score (WMD -0.35, 95% CI -1.60 to 0.90), and "off" time (WMD 0.18, 95% CI -0.14 to 0.50). No differences were found in overall withdrawals (RR 1.11, 95% CI 0.94 to 1.32), withdrawals due to adverse events (RR 1.19, 95% CI 0.91 to 1.56), or the ten commonly reported adverse events between the two formulations.

Conclusions: Our meta-analysis showed long-acting NEDAs were noninferior to standard NEDAs in efficacy, tolerability, and safety in the treatment of PD.

Citing Articles

Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis.

Chen X, Zhang Q, Chen F, Wen S, Zhou C Front Neurol. 2023; 14:1183823.

PMID: 37396766 PMC: 10312085. DOI: 10.3389/fneur.2023.1183823.

The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials.

Wu C, Guo H, Xu Y, Li L, Li X, Tang C Front Aging Neurosci. 2022; 14:831884.

PMID: 35527736 PMC: 9074827. DOI: 10.3389/fnagi.2022.831884.

Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.

Cabreira V, Soares-da-Silva P, Massano J Drugs. 2019; 79(6):593-608.

PMID: 30905034 DOI: 10.1007/s40265-019-01098-w.

Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.

Dong J, Cui Y, Li S, Le W Curr Neuropharmacol. 2015; 14(4):339-55.

PMID: 26585523 PMC: 4876590. DOI: 10.2174/1570159x14666151120123025.

Pramipexole extended-release: a review of its use in patients with Parkinson's disease.

Frampton J Drugs. 2014; 74(18):2175-90.

PMID: 25385556 DOI: 10.1007/s40265-014-0322-5.

References

Bibbiani F, Costantini L, Patel R, Chase T . Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol. 2005; 192(1):73-8. DOI: 10.1016/j.expneurol.2004.11.013. View

Elshoff J, Braun M, Andreas J, Middle M, Cawello W . Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther. 2012; 34(4):966-78. DOI: 10.1016/j.clinthera.2012.02.008. View

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

Kulisevsky J, Pagonabarraga J . Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Drug Saf. 2010; 33(2):147-61. DOI: 10.2165/11319860-000000000-00000. View

Radad K, Gille G, Rausch W . Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep. 2005; 57(6):701-12. View

Antonini A, Poewe W . Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 2007; 6(9):826-9. DOI: 10.1016/S1474-4422(07)70218-1. View

Poewe W, Rascol O, Quinn N, Tolosa E, Oertel W, Martignoni E . Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007; 6(6):513-20. DOI: 10.1016/S1474-4422(07)70108-4. View

Stockwell K, Scheller D, Smith L, Rose S, Iravani M, Jackson M . Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets. Exp Neurol. 2009; 221(1):79-85. DOI: 10.1016/j.expneurol.2009.10.004. View

Tompson D, Oliver-Willwong R . Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease. Clin Neuropharmacol. 2008; 32(3):140-8. DOI: 10.1097/WNF.0B013E318176C505. View

10.

Jenner P, Konen-Bergmann M, Schepers C, Haertter S . Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther. 2010; 31(11):2698-711. DOI: 10.1016/j.clinthera.2009.10.018. View

11.

Guldbrand Rasmussen V, Ostergaard K, Dupont E, Hvitfeldt Poulsen S . The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists. Mov Disord. 2011; 26(5):801-6. DOI: 10.1002/mds.23470. View

12.

Talati R, Reinhart K, Baker W, White C, Coleman C . Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Relat Disord. 2009; 15(7):500-5. DOI: 10.1016/j.parkreldis.2008.12.007. View

13.

Schapira A, Barone P, Hauser R, Mizuno Y, Rascol O, Busse M . Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011; 77(8):767-74. DOI: 10.1212/WNL.0b013e31822affdb. View

14.

Stocchi F, Hersh B, Scott B, Nausieda P, Giorgi L . Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008; 24(10):2883-95. DOI: 10.1185/03007990802387130. View

15.

Grosset K, Bone I, Grosset D . Suboptimal medication adherence in Parkinson's disease. Mov Disord. 2005; 20(11):1502-7. DOI: 10.1002/mds.20602. View

16.

Poewe W, Rascol O, Barone P, Hauser R, Mizuno Y, Haaksma M . Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology. 2011; 77(8):759-66. DOI: 10.1212/WNL.0b013e31822affb0. View

17.

Fernandez H . Updates in the medical management of Parkinson disease. Cleve Clin J Med. 2012; 79(1):28-35. DOI: 10.3949/ccjm.78gr.11005. View

18.

Stocchi F, Giorgi L, Hunter B, Schapira A . PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Mov Disord. 2011; 26(7):1259-65. DOI: 10.1002/mds.23498. View

19.

Giladi N, Boroojerdi B, Korczyn A, Burn D, Clarke C, Schapira A . Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007; 22(16):2398-404. DOI: 10.1002/mds.21741. View

20.

Ives N, Stowe R, Marro J, Counsell C, MacLeod A, Clarke C . Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ. 2004; 329(7466):593. PMC: 516655. DOI: 10.1136/bmj.38184.606169.AE. View